Rhinomed is a medical technology company with a patented nasal technology platform that seeks to radically improve the way you breathe, sleep, maintain your health and take medication.
Rhinomed has launched two revolutionary OTC technologies, the Turbine® – a nasal dilator designed to assist you to breathe easier during aerobic exercise, and Mute® – a nasal technology that is designed to allow you to radically improve your sleep quality by breathing more and snoring less.
Rhinomed continues to invest in furthering our knowledge of the role the nose, the upper airways and the olfactory system plays in maintaining health and wellness. It currently has a new product called INPEAP in development with a clinical program examining the impact of this new technology as a low invasive well-tolerated solution for patients suffering from mild and moderate sleep apnea. Another development program is assessing the efficacy of Rhinomed’s technology as an intranasal delivery platform for medication.
Rhinomed’s technology platform is protected by a family of over 60 patents globally. Rhinomed is listed on the Australian Stock Exchange (ASX: RNO) and headquartered in Melbourne, Australia.
Rhinomed’s nasal technology platform seeks to optimise the role the nose plays in your body’s physiology and the maintenance of good health. The technology platform aims to address significant unmet needs across four key areas of opportunity.
The Rhinomed platform is protected by a family of over 60 patents. These are granted and pending across the global market. Rhinomed continues to invest in furthering our knowledge of the role the nose, the upper airway and the olfactory system plays in maintaining health and wellness.
Rhinomed is actively seeking to partner with companies, research institutions and organisation whose interest coincide. Please reach out to us.
Rhinomed is led by a globally experienced team.
Michael is an experienced leader and innovator who has specialised in the successful commercialisation of emerging techologies and brands for over 20 years. Michael has worked in and for a wide spectrum of companies from ASX300 through to start-up companies in Life Sciences, Cleantech, Financial Services, Energy and Utilities, Manufacturing, Marketing and Communication. Michael’s most recent work has focused on helping companies envision and create new growth and innovation, manage and grow technology platforms and achieve sustainable growth through business model innovation.
Michael has been a Principal at two leading global consulting firms where he advised on innovation and competing in heavily regulated industries. Prior to that he held senior roles within some of the world’s most successful marketing and communication firms where he launched a number of high profile new products and brands. Michael received a Masters in Entrepreneurship and Innovation from Swinburne University and a Bachelor’s degree with distinction in Business from Monash University.
Ron Dewhurst has spent 40 years spread across the Investment Banking and Asset Management Industries. He has lived approximately half of his career outside his native Australia working in Hong Kong, the United Kingdom, and the United States of America. Ron has held leadership roles as CEO of Australian Investment Bank ANZ McCaughan Ltd, Managing Director of Australian asset manager IOOF Holdings Ltd, Head of Americas for J P Morgan Asset Management, and Executive Vice President and Head of Global Investment Managers for Legg Mason Inc based in the U.S.
Ron currently spends his time investing in and developing strategies in early stage companies. Ron has a long history of philanthropic pursuits including the Breast Cancer Network of Australia, The National Gallery of Victoria, The Australian World Orchestra, Playground Ideas, and Building with Books (U.S.). Ron is a strong advocate for diversity both broadly in the community, and more specifically in the business environment.
Brent is widely regarded as one of the most creative and respected business leaders in global sport. As a key innovator within Nike Inc, one of the Fortune 500’s most innovative companies, or as the founder of Unscriptd.com, Brent has helped create and change the business landscape through sport in each of the markets he has lived and worked in around the world over the last 25 years. As one of the 30 most senior leaders in the Nike Inc corporation worldwide, Brent served as part of Nike’s Global Corporate Leadership Team, where he helped lead the creation of Nike’s overall global operating strategy, as well as playing a senior role as a key member of the Global Commercial Operations Executive team, responsible for sales and distribution strategies worldwide.
More recently Brent founded Unscriptd.com (www.unscriptd.com) where he is now Chief Executive of one of the world’s fastest growing digital media companies focused solely on sport and in partnership with household names such as Andre Agassi, Steffi Graf, Cathy Freeman and Stephanie Gilmore. He currently is a non executive director at Fox Head Inc (www.foxhead.com/us) the world’s largest technical motocross and consumer products brand based in Irvine, California, USA. With over 25 years of experience in consumer innovation, business leadership, brand management, and the athletic and sports industry, Brent has developed a world-class expertise and understanding of what creates success in sports and innovative business globally.
Dr Knight has a proven track record in advising clients on strategy formulation and execution in consumer products, healthcare, and media. Eric has detailed experience in sports marketing and digital product development from ideation through to delivery. He brings significant experience leading cross- functional project teams, as well as international and multidisciplinary research teams. Eric was previously a consultant with the Boston Consulting Group, and is now based at the University of Sydney Business School, where he is an associate professor in strategic management.
Rhinomed (ASX:RNO) is pleased to advise investors that it has entered into a new distribution agreement with, and received an initial order for
stock from a new retailer. The retailer is one of America's largest pharmacy retailers.
Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The company can report record recognised revenues for FY18 Q4 of $874k - a 71% increase over FY18 Q3 and totalling $2.13m for the full FY18, up 24% on FY17.Read More
RNO is pleased to advise investors that it has signed a non-binding term sheet with Columbia Care LLC to license RNO's nasal platform for the delivery of medical cannabis and cannabinoid compounds, analogues and derivatives.Read More